© Copyright 2025 American Medical Association. All rights reserved.
The CPT® Code 85366 refers to a laboratory test that measures fibrin(ogen) degradation (split) products (FDP) (FSP) utilizing a method known as paracoagulation. This test is significant in the evaluation of the body's coagulation status, particularly in conditions where the breakdown of blood clots is a concern. Fibrin degradation products are fragments that result from the dissolution of fibrin, a protein essential for blood clot formation, which occurs when the enzyme plasmin acts on a clot. The presence of these fragments can indicate various pathological conditions, including hypercoagulation, where there is an increased tendency for blood to clot. The test specifically assesses soluble intermediates that arise during the conversion of fibrinogen to fibrin, which is a critical process in hemostasis. By employing erythrocytes that are coated with fibrin monomers, the test can detect the soluble fibrin monomer complex (SFMC), which serves as a sensitive marker for hypercoagulation. This makes the test particularly useful in diagnosing and monitoring disseminated intravascular coagulation (DIC), a serious condition characterized by widespread clotting and bleeding. To perform this test, a blood sample is collected, typically through a venipuncture, which is a separately reportable procedure. The analysis is conducted on platelet-poor plasma using qualitative hemagglutination techniques to ensure accurate measurement of the fibrin degradation products.
© Copyright 2025 Coding Ahead. All rights reserved.
The test coded as CPT® 85366 is indicated for the evaluation of conditions related to abnormal clotting and fibrinolysis. The following are specific indications for performing this test:
The procedure for conducting the test associated with CPT® 85366 involves several key steps that ensure accurate measurement of fibrin degradation products. The following outlines the procedural steps:
Post-procedure care for the patient following the blood sample collection is generally minimal. Patients may be advised to apply pressure to the venipuncture site to prevent any bleeding. It is also important to monitor for any signs of bruising or discomfort at the site. The results of the test will typically be reviewed by a healthcare professional, who will interpret the findings in the context of the patient's clinical condition. Follow-up may be necessary based on the results, especially if they indicate a need for further diagnostic evaluation or treatment for coagulation disorders.
| Short Descr | FIBRINOGEN TEST | Medium Descr | FIBRIN DGRADJ SPLT PRODUXS PARACOAGJ | Long Descr | Fibrin(ogen) degradation (split) products (FDP) (FSP); paracoagulation | Status Code | Statutory Exclusion (from MPFS, may be paid under other methodologies) | Global Days | XXX - Global Concept Does Not Apply | PC/TC Indicator (26, TC) | 9 - Not Applicable | Multiple Procedures (51) | 9 - Concept does not apply. | Bilateral Surgery (50) | 9 - Concept does not apply. | Physician Supervisions | 09 - Concept does not apply. | Assistant Surgeon (80, 82) | 9 - Concept does not apply. | Co-Surgeons (62) | 9 - Concept does not apply. | Team Surgery (66) | 9 - Concept does not apply. | Diagnostic Imaging Family | 99 - Concept Does Not Apply | CLIA Waived (QW) | No | APC Status Indicator | Conditionally packaged laboratory tests | Type of Service (TOS) | 5 - Diagnostic Laboratory | Berenson-Eggers TOS (BETOS) | T1H - Lab tests - other (non-Medicare fee schedule) | MUE | 1 | CCS Clinical Classification | 233 - Laboratory - Chemistry and Hematology |
| 90 | Reference (outside) laboratory: when laboratory procedures are performed by a party other than the treating or reporting physician or other qualified health care professional, the procedure may be identified by adding modifier 90 to the usual procedure number. | 91 | Repeat clinical diagnostic laboratory test: in the course of treatment of the patient, it may be necessary to repeat the same laboratory test on the same day to obtain subsequent (multiple) test results. under these circumstances, the laboratory test performed can be identified by its usual procedure number and the addition of modifier 91. note: this modifier may not be used when tests are rerun to confirm initial results; due to testing problems with specimens or equipment; or for any other reason when a normal, one-time, reportable result is all that is required. this modifier may not be used when other code(s) describe a series of test results (eg, glucose tolerance tests, evocative/suppression testing). this modifier may only be used for laboratory test(s) performed more than once on the same day on the same patient. | GA | Waiver of liability statement issued as required by payer policy, individual case |
|
Date
|
Action
|
Notes
|
|---|---|---|
| 2008-01-01 | Changed | Code description changed. |
| 1993-01-01 | Added | First appearance in code book in 1993. |
Get instant expert-level medical coding assistance.